# Creative Protein Frontier

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/creative-protein-frontier

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.yinjiabio.com
- Total disclosed funding: $15M
- Latest round: Series A (Jan 10, 2023)
- Investors on record: 4

## About

Established in 2020 and based in Shanghai, China, Creative Protein Frontier operates as a protein raw materials and reagents developer that provides new drugs, diagnostics, vaccines and cell therapy. The company has laboratories and R&D centers located in Shanghai, Suzhou and Beijing. In August 2021, it cooperated with IsoPlexis to establish laboratory located in Shanghai. In June 2022, Shanghai Shangyao Kangxino Biopharmaceutical Co., Ltd. became the strategic partner of the company. Yifei Wu, is the founder and CEO of the company, and once served as the executive director of protein sciences of CMC and WuXi AppTec.

The company adopts computer simulation, artificial intelligence and protein preference combination CFPS (cell free protein selective) technologies, and provides protein raw materials and reagents. Its products are divided into biological reagents and detection reagents. Biological reagents include recombinant trypsin, universal nuclease, tumor necrosis factor alpha and recombinant Tth DNA polymerase. Detection reagents provides clinical diagnostics and product solutions, including early tumor diagnosis, personalized drug guidance, targeted drug use and concomitant diagnosis. The company also provides protein customization services about protein expression systems.

## Funding rounds

- Series A, Jan 10, 2023, $15M — CMB International Asset Management, Suzhou Xinhui Boan Enterprise Management
- Angel, Feb 10, 2021 — CDH Investments, Furong Capital

## Investors

- CDH Investments (https://capitalatlas.ai/funds/cdh-investments) — Angel
- Furong Capital (https://capitalatlas.ai/funds/furong-capital) — Angel
- CMB International Asset Management (https://capitalatlas.ai/funds/cmb-international-asset-management) — Series A
- Suzhou Xinhui Boan Enterprise Management — Series A